Pfizer, Merck Get COVID Drugs OK’d, Sanofi Buys Amunix, and a New PCSK9 Contender

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.